James Trager
Chief Tech/Sci/R&D Officer chez NKARTA, INC.
Fortune : 2 M $ au 31/03/2024
Profil
James Trager is currently the Chief Scientific Officer at Nkarta, Inc. He previously worked at Dendreon Corp.
as the Senior Vice President-Research & Development from 2003 to 2019.
Trager holds a doctorate degree from the University of California, Berkeley and an undergraduate degree from St. John's College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NKARTA, INC.
0,30% | 12/02/2024 | 149 415 ( 0,30% ) | 2 M $ | 31/03/2024 |
Postes actifs de James Trager
| Sociétés | Poste | Début |
|---|---|---|
| NKARTA, INC. | Chief Tech/Sci/R&D Officer | 01/09/2016 |
Anciens postes connus de James Trager
| Sociétés | Poste | Fin |
|---|---|---|
| DENDREON CORPORATION | Chief Tech/Sci/R&D Officer | 01/12/2019 |
Formation de James Trager
| University of California, Berkeley | Doctorate Degree |
| St. John's College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NKARTA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
